ABSTRACT The psychedelic psilocybin has gained popularity in recent years as a therapy for treatment‐resistant depression and has been reported to reduce symptoms of depression and anxiety. Psilocybin's active metabolite, psilocin, possesses a binding affinity for serotonin receptors as well as for the serotonin transporter (5‐HTT). We recently reported that in contrast to wild‐type mice,...
Zusammenfassung: Hintergrund: In der Schweiz kann Psilocybin im Rahmen von Ausnahmebewilligungen therapeutisch genutzt werden. Programm: Die Klinik Südhang entwickelte basierend auf Evidenz und Ethik ein standardisiertes Programm für Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen. Das quartalsweise durchgeführte Programm umfasst Diagnostik, mehrere Einzel- und...
3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative known as an "entactogen," influencing emotional and social processing. Phase III clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder have reported promising results, and MDMA-assisted therapy is currently under regulatory review. However, the precise mechanisms underlying positive treatment...
This doctoral thesis develops a somatic psychotherapeutic framework for psychedelic-assisted therapy through interviews with twelve practitioners. Using Constructivist Grounded Theory, Heuristic Inquiry, and Integral Inquiry, it suggests that psychedelics deepen somatic experience, reopen attachment critical windows, and amplify relational processes. The framework integrates three phases:...
BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...
The renewed interest in psychedelics for mental health treatment presents both promise and complexity. Substances like psilocybin and MDMA have shown potential in addressing conditions such as PTSD and depression, particularly when administered in supportive contexts. Yet as these therapies move toward mainstream adoption, concerns arise about rapid medicalization, corporate monopolization, and...
Depressive disorder is a widespread psychological condition. It affects approximately 5% of adults globally. Untreated depression can compromise the quality of life in all its aspects, leading to deterioration of physical health or even suicide. Currently, the recommended treatment is pharmacological therapy, however, not all patients respond to traditional methods, and drug treatment is...
CellsNovember 26, 2025Ivan Anchesi, Maria Francesca Astorino, Ivana Raffaele et al.1 citation
Multiple Sclerosis (MS) therapies effectively modulate peripheral immune responses but largely fail to promote neural repair within the central nervous system. This review evaluates whether psychedelic compounds (PSYs), via 5-HT2A activation, can fill a critical therapeutic gap: the need for agents that simultaneously suppress neuroinflammation and promote regeneration. We dissect the evidence...
Psychedelics, acting primarily through 5-HT2A receptor binding and modulation of networks such as the default mode network (DMN), can induce shifts in self-perception, cognition, and emotion by promoting neuroplasticity and altering entrenched thought patterns. The biomedical model, emphasizing measurable neurochemical processes, often attempts to extract these neuroplastic benefits while...
In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments. While access remains limited, recent initiatives in Switzerland, Germany, and the Czech Republic illustrate growing momentum toward regulated use. We examine the debate surrounding psychedelics as pharmacological agents versus...